Viatris has the Financial Strength Rank of 4.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Viatris did not have earnings to cover the interest expense.
Viatris's debt to revenue ratio for the quarter that ended in Dec. 2023 was 1.20.
As of today, Viatris's Altman Z-Score is 0.94.
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris Financial Strength Distribution
For the Drug Manufacturers industry and Healthcare sector, Viatris's Financial Strength distribution charts can be found below:
* The bar in red indicates where Viatris's Financial Strength falls into.
Viatris Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Viatris's Interest Expense for the
months ended in Dec. 2023 was $-141 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-212 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16,354 Mil.
Viatris's Interest Coverage for the quarter that ended in Dec. 2023 is
| Viatris did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Viatris's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Viatris has a Z-score of 0.94, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of 0.94 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (Viatris) Business Description
Traded in Other Exchanges
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Executives
| Andrew Cuneo |
officer: See Remarks |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Xiangyang (sean) Ni |
officer: President, Greater China |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Leo Frans Groothuis |
director |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Scott Andrew Smith |
director |
C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
| Elisha W Finney |
director |
C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304 |
| Van Der Meer Mohr Pauline |
director |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Menassie Taddese |
officer: See Remarks |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Robert J Coury |
director, officer: Executive Chairman |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| W Don Cornwell |
director |
|
| Brian Roman |
officer: Global General Counsel |
1000 MYLAN BOULEVARD, CANONSBURG PA 15317 |
| Anthony Mauro |
officer: See Remarks |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| James M Kilts |
director |
120 PARK AVE, NEW YORK NY 10017 |
| Melina E Higgins |
director |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL |
| Ian C Read |
director |
PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
| Dillon Joellen Lyons |
director |
BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTRS has been successfully added to your